MDT

86.65

+0.17%↑

114.52

-0.8%↓

VEEV

174.68

+0.47%↑

HQY

84.09

-0.6%↓

PHR.US

8.67

+3.96%↑

MDT

86.65

+0.17%↑

114.52

-0.8%↓

VEEV

174.68

+0.47%↑

HQY

84.09

-0.6%↓

PHR.US

8.67

+3.96%↑

MDT

86.65

+0.17%↑

114.52

-0.8%↓

VEEV

174.68

+0.47%↑

HQY

84.09

-0.6%↓

PHR.US

8.67

+3.96%↑

MDT

86.65

+0.17%↑

114.52

-0.8%↓

VEEV

174.68

+0.47%↑

HQY

84.09

-0.6%↓

PHR.US

8.67

+3.96%↑

MDT

86.65

+0.17%↑

114.52

-0.8%↓

VEEV

174.68

+0.47%↑

HQY

84.09

-0.6%↓

PHR.US

8.67

+3.96%↑

Home・Aktien・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

BrancheGesundheitswesen

31.24 0.77

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.78

Max

32.01

Schlüsselkennzahlen
By Trading Economics
Einkommen	-14M -81M
Verkäufe	75K 75K
EPS	-1.22
Gewinnspanne	-108,422.667
Angestellte	198
EBITDA	-7.8M -81M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+73.57% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	346M 2B
Vorheriger Eröffnungskurs	30.47
Vorheriger Schlusskurs	31.24

Nachrichtenstimmung

By Acuity

100%

331 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

18.91 / 20.63 Unterstützung & Widerstand

Celldex Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2026, 04:27 UTC

Wichtige Nachrichtenereignisse

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5. Apr. 2026, 23:55 UTC

Market Talk

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5. Apr. 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5. Apr. 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Apr. 2026, 23:42 UTC

Market Talk

China's Consumer Inflation Likely Eased in March -- Market Talk

5. Apr. 2026, 23:38 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5. Apr. 2026, 12:57 UTC

Wichtige Nachrichtenereignisse

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3. Apr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 18:30 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. Apr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. Apr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. Apr. 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. Apr. 2026, 16:50 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. Apr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 16:12 UTC

Ergebnisse

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2026, 15:20 UTC

Wichtige Nachrichtenereignisse

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. Apr. 2026, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. Apr. 2026, 14:11 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. Apr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. Apr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. Apr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Celldex Therapeutics Inc Prognose

Kursziel

By TipRanks

73.57% Vorteil

12-Monats-Prognose

Durchschnitt 53.91 USD 73.57%

Hoch 90 USD

Tief 24 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Celldex Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Celldex Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

18.91 / 20.63Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.